Intra-Cellular Stock Performance

ITCI
 Stock
  

USD 55.17  1.91  3.35%   

The company retains a Market Volatility (i.e., Beta) of 0.9237, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Intra-Cellular's beta means in this case. Intra-Cellular Ther returns are very sensitive to returns on the market. As the market goes up or down, Intra-Cellular Ther is expected to follow. Even though it is essential to pay attention to Intra-Cellular Ther current price history, it is always good to be careful when utilizing equity current price movements. Our philosophy towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Intra-Cellular Ther exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Intra-Cellular Ther has an expected return of -0.12%. Please be advised to check out Intra-Cellular Ther expected short fall, and the relationship between the value at risk and daily balance of power to decide if Intra-Cellular Ther performance from the past will be repeated at some point in the near future.
  
Refresh
Intra-Cellular Performance
0 of 100
Over the last 90 days Intra-Cellular Ther has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest sluggish performance, the Stock's fundamental indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more

Intra-Cellular Price Channel

Quick Ratio8.11
Fifty Two Week Low28.40
Target High Price90.00
Fifty Two Week High66.00
Target Low Price57.00

Intra-Cellular Ther Relative Risk vs. Return Landscape

If you would invest  6,309  in Intra-Cellular Ther on April 3, 2022 and sell it today you would lose (792.00)  from holding Intra-Cellular Ther or give up 12.55% of portfolio value over 90 days. Intra-Cellular Ther is currently does not generate positive expected returns and assumes 4.4061% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Intra-Cellular, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Intra-Cellular Ther is expected to generate 3.06 times more return on investment than the market. However, the company is 3.06 times more volatile than its market benchmark. It trades about -0.03 of its potential returns per unit of risk. The DOW is currently generating roughly -0.12 per unit of risk.

Intra-Cellular Ther Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Intra-Cellular Ther's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intra-Cellular Ther, and traders can use it to determine the average amount a Intra-Cellular Ther's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0279

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsITCI
Estimated Market Risk
 4.41
  actual daily
 
 38 %
of total potential
 
3838
Expected Return
 -0.12
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.03
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Intra-Cellular Ther is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intra-Cellular Ther by adding it to a well-diversified portfolio.

About Intra-Cellular Ther Performance

To evaluate Intra-Cellular Ther Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Intra-Cellular Ther generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Intra-Cellular Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Intra-Cellular Ther stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Intra-Cellular's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Investment(53.16) (57.36) 
Return on Average Assets(0.48) (0.52) 
Return on Average Equity(0.55) (0.59) 
Return on Invested Capital(0.63) (0.65) 
Return on Sales(3.39) (3.66) 
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Things to note about Intra-Cellular Ther

Checking the ongoing alerts about Intra-Cellular Ther for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Intra-Cellular Ther help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Intra-Cellular Ther Alerts

Equity Alerts and Improvement Suggestions

Intra-Cellular Ther generated a negative expected return over the last 90 days
Intra-Cellular Ther has high historical volatility and very poor performance
Intra-Cellular Ther has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 83.8 M. Net Loss for the year was (284.13 M) with loss before overhead, payroll, taxes, and interest of (13.08 M).
Intra-Cellular Ther currently holds about 412.33 M in cash with (259.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41.
Intra-Cellular Ther has a frail financial position based on the latest SEC disclosures
Over 87.0% of the company shares are owned by institutional investors
Latest headline from www.marketwatch.com: Premarket Movers MSP Recovery, Carnival, McCormick Co - MarketWatch
Please see Risk vs Return Analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.